title: Proteomic analysis identifies candidate proteins associated with distant recurrences in breast cancer after adjuvant chemotherapy.
abstract: Breast cancer is a heterogeneous disease and it is of importance to select patients with regard to different prognosis and treatment sensitivity to individualize treatment regimes. In this study we successfully adapted a protein extraction protocol from mRNA extracted tumor samples enabling two-dimensional gel electrophoresis (2-DE) analysis of samples previously analyzed by cDNA microarray. The aim was to find candidate proteins that distinguish breast cancer patients with or without recurrences after adjuvant CMF (cyclophosphamide, methotrexate and 5-FU) treatment within four years to follow-up. We identified several proteins distinguishing the recurrence group from the non-recurrence group, especially in the ER and PgR positive subgroup (n=7). The induced proteins were involved in translation/folding, iron ion binding, and protease inhibition, whereas proteins involved in signaling, ubiquitination, and splicing were decreased in expression. These results show that it is possible to use 2-DE to separate high abundant proteins in breast cancer tissue and to find discriminating proteins to identify patients with different prognosis after adjuvant CMF treatment.
authors.affiliation: Department of Oncology, Clinical Sciences, University Hospital, Lund, Sweden.
authors.forename: Emma
authors.initials: E
authors.lastname: Niméus
authors.forename: Johan
authors.initials: J
authors.lastname: Malmström
authors.forename: Anders
authors.initials: A
authors.lastname: Johnsson
authors.forename: György
authors.initials: G
authors.lastname: Marko-Varga
authors.forename: Mårten
authors.initials: M
authors.lastname: Fernö
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015415:Biomarkers; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D015331:Cohort Studies; D003131:Combined Modality Therapy; D018076:DNA, Complementary / Q000096:biosynthesis / Q000235:genetics; D015180:Electrophoresis, Gel, Two-Dimensional; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D005782:Gels; D006801:Humans; D008207:Lymphatic Metastasis / Q000473:pathology; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D008970:Molecular Weight; D009363:Neoplasm Proteins / Q000235:genetics*; D009364:Neoplasm Recurrence, Local; D020411:Oligonucleotide Array Sequence Analysis; D040901:Proteomics
chemical_list: D015415:Biomarkers; D018076:DNA, Complementary; D005782:Gels; D009363:Neoplasm Proteins; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate